Moderna, Inc. (NASDAQ:MRNA) Holdings Cut by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. lowered its holdings in Moderna, Inc. (NASDAQ:MRNA) by 55.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,029 shares of the company’s stock after selling 8,643 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Moderna were worth $292,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of MRNA. State Street Corp increased its stake in shares of Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares during the period. Wellington Management Group LLP increased its stake in shares of Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after purchasing an additional 906,114 shares during the period. Two Sigma Advisers LP acquired a new stake in shares of Moderna in the third quarter valued at approximately $23,825,000. Douglas Lane & Associates LLC increased its stake in shares of Moderna by 62.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after purchasing an additional 298,715 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Moderna by 9.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company’s stock valued at $97,472,000 after purchasing an additional 211,426 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Moderna stock opened at $35.61 on Monday. The company has a 50 day moving average price of $36.60 and a 200 day moving average price of $48.77. Moderna, Inc. has a 52 week low of $29.25 and a 52 week high of $170.47. The firm has a market capitalization of $13.74 billion, a price-to-earnings ratio of -3.84 and a beta of 1.86.

Analysts Set New Price Targets

A number of research analysts recently commented on MRNA shares. UBS Group lowered their price objective on shares of Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. Royal Bank of Canada reiterated a “sector perform” rating and set a $40.00 price objective on shares of Moderna in a research note on Tuesday, February 18th. Evercore ISI set a $50.00 price objective on shares of Moderna in a research note on Friday, February 14th. Wolfe Research started coverage on shares of Moderna in a research note on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective on the stock. Finally, Berenberg Bank raised their price objective on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Moderna has an average rating of “Hold” and a consensus price target of $60.63.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.